Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
20-hydroxyecdysone is a naturally occurring ecdysteroid hormone found in plants and invertebrates. It is being investigated by the Research Institute of Epidemiology, Microbiology and Infectious Diseases in Uzbekistan for the treatment of giardiasis, particularly in water sports athletes. The compound exhibits a broad range of biological properties, including anabolic, antioxidant, anti-inflammatory, immunomodulatory, anti-obesity, and antidiabetic activities. While traditionally used as a dietary supplement to increase strength and muscle mass, its anti-protozoal potential is being evaluated in a Phase 2/3 randomized, double-blind, placebo-controlled study comparing it to metronidazole. The drug is administered orally at a dose of 100 mg twice daily for 10 consecutive days.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 20-hydroxyecdysone.